Literature DB >> 14763504

Insulin-induced normoglycemia reduces islet number needed to achieve normoglycemia after allogeneic islet transplantation in diabetic mice.

Juan C Ferrer-Garcia1, Juan F Merino-Torres, Gema Pérez Bermejo, Carmen Herrera-Vela, Jose L Ponce-Marco, Francisco Piñon-Selles.   

Abstract

The Edmonton protocol established that insulin independence could be reached with the transplantation of an appropriate number of islet cells. However, to effect a cure, islets from two or three pancreases are needed. The aim of this study was to examine whether normoglycemia, with insulin treatment before and after transplantation, reduces the islet number needed to achieve normoglycemia in allogeneic islet transplantation. Swiss mice were used as donors and recipients. Diabetes was induced by i.p. administration of streptozotocin (180 mg/kg BW). Diabetic mice were transplanted with 300 (n = 16), 400 (n = 16), or 500 (n = 16) islets under the left kidney capsule. For every group, half the animals were kept normoglycemic with insulin treatment from day 4 before transplantation to day 10 after transplantation. At the end of the study, all normoglycemic mice were given an i.p. glucose tolerance test (IPGTT). For statistical analysis, paired or unpaired Student's t-test or ANOVA was used. Only insulin-treated mice achieved normoglycemia by the end of the study (37.5% of animals transplanted with 400 islets and 50% transplanted with 300 or 500 islets). At the end of the study, normoglycemic mice transplanted with 300 allogeneic islets showed better glycosylated hemoglobin (HbA1C) than did normoglycemic mice transplanted with 500 islets (300 islets: 2.7 +/- 0.2%; 500 islets: 3.6 +/- 0.2%; p < 0.05). After the IPGTT, insulin-treated mice transplanted with 500 islets showed abnormal glucose tolerance; however, insulin-treated mice transplanted with 300 or 400 islets showed normal glucose tolerance. Insulin treatment reduced the islet number needed to achieve normoglycemia in allogeneic islet transplantation. The HbA1C and IPGTT results suggest that transplanting smaller numbers of allogeneic islets improves beta-cell function; some studies suggest that this may be due to lower immunogenicity, hypoxia, and inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14763504

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  5 in total

1.  Near-euglycemia can be achieved safely in pediatric total pancreatectomy islet autotransplant recipients using an adapted intravenous insulin infusion protocol.

Authors:  Gregory P Forlenza; Srinath Chinnakotla; Sarah J Schwarzenberg; Marie Cook; David M Radosevich; Carol Manchester; Sameer Gupta; Brandon Nathan; Melena D Bellin
Journal:  Diabetes Technol Ther       Date:  2014-07-28       Impact factor: 6.118

2.  Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment.

Authors:  A King; J Lock; G Xu; S Bonner-Weir; G C Weir
Journal:  Diabetologia       Date:  2005-08-23       Impact factor: 10.122

3.  Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation.

Authors:  G P Forlenza; B M Nathan; A M Moran; T B Dunn; G J Beilman; T L Pruett; M D Bellin
Journal:  Am J Transplant       Date:  2015-11-20       Impact factor: 8.086

4.  Leptin administration enhances islet transplant performance in diabetic mice.

Authors:  Heather C Denroche; Whitney L Quong; Jennifer E Bruin; Eva Tudurí; Ali Asadi; Maria M Glavas; Jessica K Fox; Timothy J Kieffer
Journal:  Diabetes       Date:  2013-05-08       Impact factor: 9.461

5.  Implanting 1.1B4 human β-cell pseudoislets improves glycaemic control in diabetic severe combined immune deficient mice.

Authors:  Alastair D Green; Srividya Vasu; Neville H McClenaghan; Peter R Flatt
Journal:  World J Diabetes       Date:  2016-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.